| Dr Katherine Gehlmann Conner, MD | |
|
9301 Golf Rd Ste 301, Des Plaines, IL 60016-7900 | |
| (847) 635-7300 | |
| (847) 635-7556 |
| Full Name | Dr Katherine Gehlmann Conner |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 15 Years |
| Location | 9301 Golf Rd Ste 301, Des Plaines, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720216120 | NPI | - | NPPES |
| F400166785 | Other | IL | MEDICARE PTAN |
| 36129920 | Medicaid | IL | |
| F400166787 | Other | IL | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 036.129920 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Partners Pllc | 7113822420 | 149 |
News Archive
BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
Scientists are making strides in understanding how the malaria parasite Plasmodium falciparum disguises itself to avoid detection by the immune system. The findings could lead to the development of new drugs for a disease that causes more than 300 million acute illnesses and at least one million deaths each year, most of them in developing countries.
Imagine seeing the world in muted shades - gray sky, gray grass. Some people with color blindness see everything this way, though most can't see specific colors.
An international stroke study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.
› Verified 6 days ago
| Entity Name | Allergy Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265701023 PECOS PAC ID: 7113822420 Enrollment ID: O20120611000214 |
News Archive
BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
Scientists are making strides in understanding how the malaria parasite Plasmodium falciparum disguises itself to avoid detection by the immune system. The findings could lead to the development of new drugs for a disease that causes more than 300 million acute illnesses and at least one million deaths each year, most of them in developing countries.
Imagine seeing the world in muted shades - gray sky, gray grass. Some people with color blindness see everything this way, though most can't see specific colors.
An international stroke study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katherine Gehlmann Conner, MD Po Box 603725, Charlotte, NC 28260-3725 Ph: (828) 575-2625 | Dr Katherine Gehlmann Conner, MD 9301 Golf Rd Ste 301, Des Plaines, IL 60016-7900 Ph: (847) 635-7300 |
News Archive
BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
Scientists are making strides in understanding how the malaria parasite Plasmodium falciparum disguises itself to avoid detection by the immune system. The findings could lead to the development of new drugs for a disease that causes more than 300 million acute illnesses and at least one million deaths each year, most of them in developing countries.
Imagine seeing the world in muted shades - gray sky, gray grass. Some people with color blindness see everything this way, though most can't see specific colors.
An international stroke study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.
› Verified 6 days ago
Dr. Sahar K. Rida, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 380 E Northwest Hwy, Suite 310, Des Plaines, IL 60016 Phone: 847-954-0112 Fax: 847-954-0313 | |
Waheeda M Hirani, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9301 Golf Rd Ste 301, Des Plaines, IL 60016 Phone: 847-635-7300 Fax: 847-635-7556 | |
Dr. Suellyn S Rossman, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2434 E Dempster St Ste 206, Des Plaines, IL 60016 Phone: 847-297-2474 Fax: 847-297-2476 | |
Sol Drapkin, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9301 Golf Rd Ste 301, Des Plaines, IL 60016 Phone: 847-635-7300 Fax: 847-635-7556 |